Drug data last refreshed 18h ago · AI intelligence enriched 1mo ago
HELIUM, USP is an inhaled gas product approved by FDA in July 2021 for use as a medical gas therapeutic. The product is a non-pharmacological inhalation agent with no traditional mechanism of action or pharmacologic class. Patient populations and clinical indications are not publicly detailed in available regulatory records.
Product is at peak lifecycle stage with moderate competitive pressure (30), suggesting stable commercial operations but limited growth runway for team expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
C2 Esophageal Squamous Epithelium Dysplasia
Worked on HELIUM, USP at Advanced Solutions Life Sciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on HELIUM offers exposure to specialty medical gas commercialization and post-approval safety management, with strong focus on regulatory compliance and adverse event monitoring given the serious safety signals. Career progression depends on commercial execution in a niche market with moderate competition and limited patent-driven growth potential.